VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Technical Scanner
RSI, Moving averages & volume momentum signals
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
Minervini — VCPContraction bases in Stage 2 uptrends
Minervini — Trend TemplateFull 8-rule Stage 2 screen
O'Neil — Cup with HandleBase breakouts with RS leadership
O'Neil — CANSLIM LeadersGrowth leaders with RS ≥ 85
Qullamaggie — High Tight FlagsPower plays after a large advance
Qullamaggie — Momentum Leaders1/3/6-month strength leaders
Livermore — Pivotal PointsMulti-touch resistance breakouts
View All Playbooks...
Breakouts
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
Breakouts
WatchlistPricing
Ctrl K
Pricing
ALKS
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsCompareWatchlist
ALKSAlkermes plc
$42.13$7.1B
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HomeStocksALKSP/E History

ALKS logoAlkermes plc (ALKS) P/E Ratio History

Undervalued

Trading at 29.5x vs 5Y avg 78.3x · 65th percentile · Below historical baseline · Data 2006–2026

Current P/E (TTM)
29.5x
-62% vs 5Y avg
5Y Avg P/E
78.3x
Median 15.8x
5Y Percentile
65th
Mid-range
PEG Ratio
N/A
5-Year P/E Range
29.5x
Min8.9xMedian15.8xMax467.1x
TTM EPS$0.40
Price$42.13
Earnings Yield3.39%
EPS Growth (1Y)-34.1%
EPS Growth (5Y)N/A

Loading P/E history...

P/E Ratio Analysis

As of September 24, 2026, Alkermes plc (ALKS) trades at a price-to-earnings ratio of 29.5x, with a stock price of $42.13 and trailing twelve-month earnings per share of $0.40.

The current P/E is 62% below its 5-year average of 78.3x. Over the past five years, ALKS's P/E has ranged from a low of 8.9x to a high of 467.1x, placing the current valuation at the 65th percentile of its historical range.

Compared to the Healthcare sector median P/E of 23.7x, ALKS trades at a 24% premium to its sector peers. The sector includes 225 companies with P/E ratios ranging from 0.0x to 167.0x.

Relative to the broader market, ALKS trades roughly in line with the S&P 500 median P/E of 25.3x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.

For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our ALKS DCF Valuation Calculator →

Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.

ALKS Cross-Benchmark Valuation

How does the current P/E compare to sector peers and the broader market?

vs. Healthcare
29.5vs23.7
+24%
Above Sector
vs. S&P 500
29.5vs25.3
+16%
Above Market
PEG Analysis
N/A
P/E ÷ EPS Growth
Based on -34% EPS growth (1Y)

ALKS P/E vs Peers

Commercial Specialty Pharma peers sorted by market cap

CompanyMarket CapP/E RatioPEG RatioEPS Growth (1Y)
INVA logoINVAInnoviva, Inc.
$1B6.1Lowest0.59+817%Best
ACAD logoACADACADIA Pharmaceuticals Inc.
$4B11.1-+68%
INTR logoINTRInter & Co, Inc.
$2B9.40.06Best+40%
TEVA logoTEVATeva Pharmaceutical Industries Limited
$46B32.5-+183%
BHC logoBHCBausch Health Companies Inc.
$2B13.3-+431%
COLL logoCOLLCollegium Pharmaceutical, Inc.
$728M13.00.73-7%
AVPT logoAVPTAvePoint, Inc.
$3B87.5-+194%

Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.

ALKS Historical P/E Data (2006–2026)

Quarterly P/E ratios calculated from closing price and TTM EPS

QuarterPeriod EndPriceTTM EPSP/E Ratiovs Avg
FY2026 Q2-$52.40$0.38136.8x+73%
FY2026 Q1-$35.36$0.9039.3x-50%
FY2025 Q4Dec 31 2025$27.98$1.4319.6x-75%
FY2025 Q3-$30.00$2.0214.9x-81%
FY2025 Q2Jun 30 2025$28.61$2.0813.8x-83%
FY2025 Q1Mar 31 2025$33.02$2.0915.8x-80%
FY2024 Q4-$28.76$2.1713.3x-83%
FY2024 Q3Sep 30 2024$27.99$1.9514.4x-82%
FY2024 Q2Jun 30 2024$24.10$1.6814.3x-82%
FY2024 Q1Mar 31 2024$27.07$2.5310.7x-86%
FY2023 Q4Dec 31 2023$27.74$2.0713.4x-83%
FY2023 Q3Sep 30 2023$28.01$1.2422.6x-71%
FY2023 Q2Jun 30 2023$31.30$0.5754.9x-30%
FY2013 Q4-$40.66$0.13302.5x+283%
FY2013 Q3Sep 30 2013$33.62$0.13250.1x+217%
FY2013 Q2Jun 30 2013$28.68$0.06467.1x+492%
FY2013 Q1Mar 31 2013$23.70$0.18130.7x+65%
FY2009 Q3Sep 30 2009$9.19$0.8411.0x-86%
FY2009 Q2-$10.82$0.9511.4x-86%
FY2009 Q1-$12.13$1.378.9x-89%
FY2008 Q4Dec 31 2008$10.65$1.328.1x-90%
FY2008 Q3-$13.30$1.777.5x-90%
FY2008 Q2Jun 30 2008$12.36$1.826.8x-91%
FY2008 Q1Mar 31 2008$11.88$1.597.5x-91%
FY2007 Q4Dec 31 2007$15.59$1.818.6x-89%
FY2007 Q3Sep 30 2007$18.40$0.2186.0x+9%
FY2007 Q2Jun 30 2007$14.60$0.1879.3x+0%
FY2007 Q1Mar 31 2007$15.44$0.09164.3x+108%
FY2006 Q4Dec 31 2006$13.37$0.1587.0x+10%
FY2006 Q3Sep 30 2006$15.85$0.13118.5x+50%
FY2006 Q2Jun 30 2006$18.92$0.2188.5x+12%
FY2006 Q1Mar 31 2006$22.05$0.07299.2x+279%

Average P/E for displayed period: 79.0x

Export Data
Consensus & Technical Research Suite
Open ALKS Terminal

ALKS Chart Terminal

WASM

Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.

Launch Terminal

Live Breakouts Feed

LIVE

High-probability breakout stocks crossing their pivot across 5 pattern engines.

Explore Setups

Intrinsic Valuation

DCF models, multiple analysis, and analyst estimates.

Check Valuation

Historical Returns

20+ years return with dividends reinvested.

Calculate

Peer Comparison

Compare growth, multiples, and margins vs sector.

Compare

ALKS — Frequently Asked Questions

Quick answers to the most common questions about buying ALKS stock.

What is ALKS's P/E ratio?

Alkermes plc (ALKS) trailing twelve-month P/E ratio is 29.5x, based on TTM diluted EPS of $0.40. The 5-year average P/E is 78.3x and the historical range spans 8.9x to 467.1x.

Is ALKS stock overvalued or undervalued?

ALKS trades at 29.5x P/E, below its 5-year average of 78.3x. At the 65th percentile of its historical range (8.9x–467.1x), the stock is priced at a discount to its own history.

Is ALKS stock expensive?

No, ALKS is not expensive on a historical basis. The current P/E of 29.5x is below the 5-year average of 78.3x and sits at the 65th percentile of its valuation range.

What is ALKS's historical P/E range?

Over the past 5 years, ALKS's P/E ratio has ranged from 8.9x to 467.1x, with a median of 15.8x and an average of 78.3x. The current P/E of 29.5x places the stock at the 65th percentile of this range. Full historical data spans 2006–2026.

How does ALKS's P/E compare to the S&P 500?

ALKS trades at 29.5x P/E versus the S&P 500 median of 25.3x. The 17% premium to the market typically reflects higher expected earnings growth or quality.

How does ALKS's valuation compare to Healthcare peers?

Alkermes plc P/E of 29.5x compares to the Healthcare sector median of 23.7x. The premium reflects expected growth above peers or stronger fundamentals. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.

What is ALKS's PEG ratio?

ALKS PEG ratio is N/A, based on a P/E of 29.5x and EPS growth of -34.1%. PEG normalises P/E by growth and helps compare stocks with different earnings trajectories.

What is ALKS's earnings yield?

ALKS earnings yield is 3.39%, the inverse of its 29.5x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.

ALKS P/E Ratio History (2006–2026)

Quarterly valuation multiple from closing price and trailing EPS

Current136.8x
Period Avg78.3x
Range8.9x - 467.1x
Change+1445%
20 quartersMar 31, 2009 - Jun 30, 2026